EUR-Lex Access to European Union law

Back to EUR-Lex homepage

This document is an excerpt from the EUR-Lex website

Document 52022M10680

Prior notification of a concentration (Case M.10680 – PERMIRA / SESTANT / KEDRION / BPL) (Text with EEA relevance) 2022/C 277/07

PUB/2022/849

OJ C 277, 19.7.2022, p. 10–11 (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

19.7.2022   

EN

Official Journal of the European Union

C 277/10


Prior notification of a concentration

(Case M.10680 – PERMIRA / SESTANT / KEDRION / BPL)

(Text with EEA relevance)

(2022/C 277/07)

1.   

On 8 July 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings:

Permira Holdings Limited (‘Permira’, Guernsey),

Sestant Internazionale S.p.A. (‘Sestant’, Italy), controlled by members of the Marcucci family,

Kedrion S.p.A. (‘Kedrion’, Italy), ultimately controlled by Sestant,

Bio Products Laboratory Holdings Limited (‘BPL’, United Kingdom), controlled by Tiancheng International Investment Limited (China).

Permira and Sestant will acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of Kedrion and BPL.

The concentration is accomplished by way of purchase of shares.

2.   

The business activities of the undertakings concerned are the following:

Permira is a European private equity firm, which makes private equity investments in companies active in a wide variety of sectors,

Sestant is a financial holding company overseeing the international assets of the Marcucci family,

Kedrion is the parent company of a global biopharmaceutical group specialising in the collection of human plasma and the development, production and sale of therapeutic plasma-derived products,

BPL operates plasma collection centres across the US and produces a range of plasma-derived products for the treatment of immune deficiencies, bleeding disorders and infectious diseases, as well as for critical care.

3.   

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.   

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10680 – PERMIRA / SESTANT / KEDRION / BPL

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË


(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).


Top